90798-12-2

Basic information

• Product Name: 3-(acetyloxy)-4-methoxybenzoyl chloride
• Synonyms: 3-(acetyloxy)-4-methoxybenzoyl chloride
• CAS NO: 90798-12-2
• Molecular Weight: 228.632
• Mol File: 90798-12-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-(acetyloxy)-4-methoxybenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(acetyloxy)-4-methoxybenzoyl chloride(90798-12-2)
• EPA Substance Registry System: 3-(acetyloxy)-4-methoxybenzoyl chloride(90798-12-2)

Safety Data

• Hazardous Substances Data: 90798-12-2(Hazardous Substances Data)

Upstream product

• 645-08-9 Isovanillic acid 
• 79-37-8 oxalyl dichloride 
• 60444-56-6 3-acetoxy-4-methoxybenzoic acid 

Downstream Products

• 1257321-37-1 N'-(3-hydroxy-4-methoxybenzoyl)-3,4,5-trimethoxybenzohydrazide 
• 1195941-41-3 2-{3-[2-(3-methanesulfinyl-phenyl)-ethoxy]-4-methoxy-benzoylamino}-indane-2-carboxylic acid 
• 1195941-39-9 2-{4-methoxy-3-[2-(3-methylsulfanyl-phenyl)-ethoxy]-benzoylamino}-indane-2-carboxylic acid methyl ester 
• 1195941-40-2 2-{4-methoxy-3-[2-(3-methylsulfanyl-phenyl)-ethoxy]-benzoylamino}-indane-2-carboxylic acid 
• 1195942-31-4 2-(3-benzenesulfonyloxy-4-methoxy-benzoylamino)-indane-2-carboxylic acid 
• 1195944-90-1 2-(3-hydroxy-4-methoxy-benzoylamino)-indane-2-carboxylic acid methyl ester 
• 1613391-30-2 5-[5-(3-chloroanilino)-4H-1,2,4-triazol-3-yl]-2-methoxyphenol 
• 1613391-29-9 N-[(3-chlorophenyl)carbamothioyl]-3-acetoxy-4-methoxybenzamide 
• 520-34-3 diosmetin 
• 1195944-89-8 2-(3-acetoxy-4-methoxy-benzoylamino)-indane-2-carboxylic acid methyl ester 
• 21736-96-9 quercatin 7,4'-dimethyl ether triacetate 
• 243136-42-7 3-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-5,7-dimethoxy-4H-chromen-4-one 
• 529-40-8 ombuin 
• 603-61-2 tamarixetin 

Relevant articles and documents

Tubulin inhibitors: Discovery of a new scaffold targeting extra-binding residues within the colchicine site through anchoring substituents properly adapted to their pocket by a semi-flexible linker

Bis-hydrazides 13a-h were designed and synthesized as potential tubulin inhibitors selectively targeting the colchicine site between α- and β-tubulin subunits. The newly designed ring-B substituents were assisted at their ends by ‘anchor groups’ which are expected to exert binding interaction(s) with new additional amino acid residues in the colchicine site (beyond those amino acids previously reported to interact with reference inhibitors as CA-4 and colchicine). Conformational flexibility of bis-hydrazide linker assisted these ‘extra-binding’ properties through reliving ligands’ strains in the final ligand-receptor complexes. Compound 13f displayed the most promising computational and biological study results in the series: MM/GBSA binding energy of ?62.362 kcal/mol (extra-binding to Arg α:221, Thr β:353 & Lys β:254); 34% NCI-H522 cells’ death (at 10 μM), IC50 = 0.073 μM (MTT assay); significant cell cycle arrest at G2/M phase; 11.6% preG1 apoptosis induction and 83.1% in vitro tubulin inhibition (at concentration = IC50). Future researchers in bis-hydrazide tubulin inhibitors are advised to consider the 2-chloro-N-(4-substituted-phenyl)acetamide derivatives as compound 13f due to extra-binding properties of their ring B.

ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibi

Compounds and compositons for treating C1s-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.